Bioxcel Therapeutics Inc (BTAI) Stock Price, Quote & News

Latest News on BTAI

Mar 7, 2025, 7:00 AM EST - 1 day ago

BioXcel Therapeutics Announces 33% Enrollment in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

Mar 4, 2025, 4:15 PM EST - 4 days ago

BioXcel Therapeutics Announces Closing of $14 Million Registered Direct Offering

Mar 3, 2025, 3:33 PM EST - 5 days ago

BioXcel Therapeutics Announces $14 Million Registered Direct Offering

Mar 3, 2025, 7:00 AM EST - 5 days ago

BioXcel Therapeutics Announces FDA Closed its Inspection of Site for Phase 3 TRANQUILITY II Trial for Acute Treatment of Agitation Associated with Alzheimer's Dementia

Feb 28, 2025, 7:00 AM EST - 8 days ago

BioXcel Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule

Feb 6, 2025, 7:00 AM EST - 4 weeks ago

BioXcel Therapeutics Announces Reverse Stock Split

Nov 22, 2024, 8:16 AM EST - 3 months ago

BioXcel Therapeutics Announces Pricing of $7.0 Million Public Offering

Nov 21, 2024, 4:47 PM EST - 3 months ago

BioXcel Therapeutics Announces Proposed Public Offering

Nov 14, 2024, 9:07 AM EST - 4 months ago

BioXcel Therapeutics, Inc. (BTAI) Q3 2024 Earnings Call Transcript

Nov 8, 2024, 7:00 AM EST - 4 months ago

BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024

Oct 29, 2024, 7:00 AM EDT - 4 months ago

BioXcel Therapeutics to Present at ThinkEquity Conference

Oct 15, 2024, 7:00 AM EDT - 5 months ago

BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder

Sep 19, 2024, 7:00 AM EDT - 6 months ago

BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for Agitation

Sep 5, 2024, 7:00 AM EDT - 6 months ago

BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

Aug 9, 2024, 9:48 PM EDT - 7 months ago

BioXcel Therapeutics, Inc. (BTAI) Q2 2024 Earnings Call Transcript

Jul 16, 2024, 7:00 AM EDT - 8 months ago

BioXcel Therapeutics Announces Preliminary Estimated Unaudited Second Quarter Net Revenues from Sales of IGALMI™ (dexmedetomidine) Sublingual Film

May 28, 2024, 7:00 AM EDT - 10 months ago

BioXcel Therapeutics to Present at Jefferies Global Healthcare Conference

May 21, 2024, 7:00 AM EDT - 10 months ago

BioXcel Therapeutics Announces Oral and Poster Presentations at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

May 9, 2024, 9:53 AM EDT - 10 months ago

BioXcel Therapeutics, Inc. (BTAI) Q1 2024 Earnings Call Transcript

May 9, 2024, 7:00 AM EDT - 10 months ago

BioXcel Therapeutics Reports First Quarter 2024 Financial Results

Apr 25, 2024, 7:00 AM EDT - 11 months ago

BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024

Apr 24, 2024, 10:30 AM EDT - 11 months ago

BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting

Apr 22, 2024, 7:00 AM EDT - 11 months ago

BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential

Apr 10, 2024, 7:00 AM EDT - 11 months ago

BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer's Dementia

Mar 25, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Announces $25 Million Registered Direct Offering

Mar 15, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Announces European Patent Office's Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine

Mar 12, 2024, 11:00 AM EDT - 1 year ago

BioXcel Therapeutics, Inc. (BTAI) Q4 2023 Earnings Call Transcript

Mar 12, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023

Mar 1, 2024, 7:00 AM EST - 1 year ago

BioXcel Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024

Feb 13, 2024, 9:00 AM EST - 1 year ago

BioXcel Therapeutics Announces Termination of Proposed Public Offering

Feb 12, 2024, 7:14 AM EST - 1 year ago

BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC)

Feb 6, 2024, 7:00 AM EST - 1 year ago

BioXcel Therapeutics Announces Completion of Patient Enrollment in Safety Portion of Investigator-Sponsored Phase 2 Relapsed Pancreatic Cancer Trial of BXCL701 in Combination with KEYTRUDA®

Feb 5, 2024, 7:00 AM EST - 1 year ago

BioXcel Therapeutics Announces USPTO's Allowance of Patent Application for Method of Treating Agitation in Alzheimer's Disease Using Oromucosal Formulations of Dexmedetomidine

Dec 12, 2023, 7:00 AM EST - 1 year ago

BioXcel Therapeutics Hosting Virtual Neuroscience R&D Day Today

Dec 11, 2023, 7:00 AM EST - 1 year ago

BioXcel Therapeutics Strengthens Clinical Development Leadership to Advance Late-Stage Programs

Nov 30, 2023, 7:00 AM EST - 1 year ago

BioXcel Therapeutics to Host Virtual Neuroscience R&D Day on Dec. 12, 2023

Nov 14, 2023, 10:27 AM EST - 1 year ago

BioXcel Therapeutics, Inc. (BTAI) Q3 2023 Earnings Call Transcript

Nov 14, 2023, 7:00 AM EST - 1 year ago

BioXcel Therapeutics Aligns with FDA Recommendation for Phase 3 Trial for TRANQUILITY Program, Provides Update on Strategic Financing, and Reports Third Quarter 2023 Financial Results

Nov 8, 2023, 7:00 AM EST - 1 year ago

BioXcel Therapeutics Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) of Adenocarcinoma Phenotype

Nov 6, 2023, 7:00 AM EST - 1 year ago

BioXcel Therapeutics Announces Update on NIDA-funded Trial of BXCL501 (sublingual dexmedetomidine) for Potential Treatment of Opioid Use Disorder (OUD)

Oct 31, 2023, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics to Report Third Quarter 2023 Financial Results on November 14, 2023

Oct 30, 2023, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Receives Permanent J-Code for IGALMI™ (dexmedetomidine) Sublingual Film from Centers for Medicare & Medicaid Services

Oct 25, 2023, 8:44 AM EDT - 1 year ago

BioXcel Therapeutics shares pop after audit of Alzheimer's trial data

Oct 25, 2023, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Announces Positive Findings from Independent Third Party Audit of Data Integrity at TRANQUILITY II Phase 3 Trial Site

Oct 10, 2023, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Small Cell Neuroendocrine Prostate Cancer

Oct 4, 2023, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Provides Update on Recent Developments for Late-Stage Clinical Programs and Expansion of IP Portfolio for IGALMI™ (dexmedetomidine) Sublingual Film

Sep 5, 2023, 6:00 AM EDT - 1 year ago

FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in BioXcel Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Sep 4, 2023, 1:30 PM EDT - 1 year ago

Market Cap	8.78M
Revenue (ttm)	1.38M
Net Income (ttm)	-179.05M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-12,974.64%
Debt to Equity Ratio	-1.22

Volume	2,508,900
Avg Vol	5,466,395
Day's Range	N/A - N/A
Shares Out	3.21M
Stochastic %K	32%
Beta	0.89
Analysts	Sell
Price Target	$32.80